Loading...

Zinbryta (daclizumab) Brain Inflammation Lawsuits

Biogen Inc. and AbbVie Inc. have been under fire as of late due to their multiple sclerosis drug Zinbryta (daclizumab).  So much so that the multimillion-dollar making drug has been pulled from the market worldwide and the number of Zinbryta (daclizumab) brain inflammation lawsuits are on the rise. Reports of encephalitis, meningoencephalitis and wrongful deaths are coming from all over the world linking the new multiple sclerosis injection Zinbryta (daclizumab) to said illnesses and deaths.

The defective drug attorneys at Jones Brown PLLC are currently accepting cases against the drug Zinbryta(daclizumab)  and it’s makers Biogen Inc. and Abbvie Inc. To help us determine if you may be entitled to compensation through a Zinbryta brain inflammation lawsuit, CLICK HERE to jump straight to our Defective Drug Evaluation.

Zinbryta Side Effects and Recall:

Zinbryta (daclizumab) is a multiple sclerosis injection drug that was introduced in 2016, for the treatment of adult patients with relapsing forms of multiple sclerosis. Due to a risk of liver injury linked to Zinbryta side effects, the drug was only available through to a Risk Evaluation and Mitigation Strategy (REMS) program in the U.S., and regulators only recommended it as a treatment for individuals who have failed to respond to other first-line MS drugs due to severe liver toxicity risks.

Less than two years after the drug was introduced, a worldwide Zinbryta recall was announced in March 2018, following at least 12 reported cases of Zinbryta encephalitis and meningoencephalitis, which causes swelling and inflammation in the brain. At least three of those brain problems on Zinbryta resulted in death, with each of those instances occurring in the United States. It does not appear that users or the medical community were adequately warned about the risk of brain inflammation on Zinbryta or the importance of monitoring for symptoms like:

  • Severe Headaches
  • Nausea and Vomiting
  • Persistent Fever
  • Fatigue
  • Yellowing of the Skin or Eyes

In a press release issued on March 2, 2018, the drugmakers, Biogen and AbbVie, indicated that they as the makers of Zinbryta were unable to properly characterize the brain inflammation risks associated with their drug given the limited number of individuals being treated. Therefore the medication was “voluntarily removed from the market worldwide. There have been an estimated 8,000 individuals treated with Zinbryta. However, an investigation by the European Medicines Agency announced this week indicated:

  • At least 12 Zinbryta brain inflammation cases have been identified;
  • Most problems occurred within 8 months of starting treatment;
  • At least 3 deaths from Zinbryta were among the reports of inflammatory brain disorders reviewed;
  • Individuals prescribed Zinbryta should not take another injection and should contact their doctor to discuss treatment options;
  • Regular blood tests should be continued for up to 6 months after stopping the drug to check for Zinbryta side effects

Zinbryta Brain Inflammation Lawsuits

For anyone that was prescribed and used the multiple sclerosis injections that have been diagnosed with encephalitis, meningoencephalitis or another brain inflammation problem on Zinbryta, financial compensation may be available due to the drug makers’ failure to properly research the side effects of the drug. Potential Zinbryta wrongful death lawsuits are also being evaluated for families of any individuals who may have died after use of the medication.

Zinbryta Brain Inflammation Lawsuit Attorney

Contact Jones Brown PLLC

Our Jones Brown Law team has experience helping countless victims of defective drugs and devices.  We understand each case is different, however,  we will help you recover what you are entitled to and we understand what you are going through when you are dealing with a defective drug lawsuit.

The Jones Brown team of defective drug lawyers and attorneys are now reviewing whether individuals throughout the United States may be entitled to financial compensation through Zinbryta brain inflammation lawsuits or Zinbryta wrongful death lawsuits, as a result of the drug makers’ failure to adequately research the medication and warn about potential side effects. To help us determine if you may be entitled to compensation through a Zinbryta brain inflammation lawsuit, CLICK HERE to jump straight to our Defective Drug Evaluation.

Do You Have Questions? We Have Answers. Talk to a Jones Brown Attorney Now.

Contact Jones Brown

At Jones Brown, we’ve made it our mission to provide legal representation of the highest caliber at a rate that is affordable to everyone. Our goal is to make legal representation and services attainable for all those who seek it, without the need to compromise ethics, experience, or quality of service. All of our attorneys adhere to a strict code of professional ethics, upholding our Client Bill of Rights, to ensure that our clients are treated with the respect and attention they deserve.

Share Page